Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby
BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...
BridgeBio heart drug approved by FDA, setting up battle with Pfizer
The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...
STAT22h
BridgeBio wins FDA approval for heart disease drug
The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...
The Heart of the Matter
If you or someone you love has heart failure and unresolved, seemingly unrelated symptoms such as carpal tunnel syndrome, shortness of breath, irregular heartbeat, or even lower back pain, it could be ...
Ultromics obtains Breakthrough Device FDA clearance for its Cardiac Amyloidosis screening device through the Total Product Lifecycle Advisory Program
Ultromics' EchoGo® Amyloidosis, clinical AI for echocardiography with the potential to revolutionize early detection of ...
News Medical3d
CRISPR-based therapy shown to be safe, effective for people with transthyretin amyloidosis
Results for the Phase I clinical trial, published in the New England Journal of Medicine, bring hope for people with transthyretin amyloidosis (ATTR), who have ... and slowing down the progression of ...
Study highlights physician perspectives on emerging anti-amyloid treatments for Alzheimer's disease
In a recent study, Tel Aviv Sourasky Medical Center has shed light on physician attitudes toward novel anti-amyloid ...
STAT4d
Two drugs look promising for lipoprotein(a), a common genetic risk factor for heart disease
At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...
Pharmaceutical Technology5d
Intellia’s gene editing therapy shows early potential in rare heart condition
Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...
BioSpace5d
Intellia’s CRISPR Gene Editor Shows Early Promise With Strong Biomarker Benefit in ATTR Amyloidosis
Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...
Live Science6d
Women are at higher risk of dying from heart disease. Here's why.
Here’s how it works. A simple difference in the genetic code — two X chromosomes versus one X chromosome and one Y chromosome ...
Business Insider11d
Attralus Therapeutic AT-02 Receives Orphan Drug Designation from the U.S. FDA for the Treatment of ATTR Amyloidosis
ATTR is a systemic disease caused by accumulation of amyloid deposits in various parts of the body, including the heart, nerves, connective tissue, kidney and gastrointestinal tract. Patients with ...